Cypherpunk Technologies increased its Zcash treasury to 314,185.70 ZEC and invested $5 million in Zcash Open Development Labs to support privacy tech. Its subsidiary Leap Therapeutics received FDA Fast Track for sirexatamab in colorectal cancer and presented positive clinical data. The company reported a $77.2 million net loss in Q1 2026, mainly due to unrealized losses from Zcash price declines. Cypherpunk continues to focus on privacy technology and digital asset growth amid market volatility.
Block cut its workforce by over 4,000 in early 2026, yet posted a 51.8% growth in Q1 adjusted EPS and raised its full-year guidance by 62%. CEO Jack Dorsey credits AI tools, used by all employees, for enabling a smaller team to increase productivity ...
The Benchmark Company, a subsidiary of StoneX Group Inc., will hold its Digital Assets Summit in New York City on May 27, 2026. The event aims to connect leading public and private digital asset and crypto companies with institutional investors throu...
Crypto-linked stocks like Coinbase, MicroStrategy, and Marathon Digital rallied strongly on May 14, driven by optimism around the Senate Banking Committee's upcoming vote on the Digital Asset Market Clarity Act. This legislation aims to clarify regul...
The US Senate is set to address the long-delayed CLARITY Act, a bill that would create a regulatory framework for cryptocurrencies. The legislation aims to define when crypto tokens are securities or commodities, providing legal clarity for the indus...
